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Objectives: The clinical course and complications of malaria during pregnancy are exacerbated 
in HIV-positive women. Furthermore, malaria during pregnancy may increase the risk of mother 
to child transmission (MTCT) of HIV. We assessed the uptake of WHO recommended 
intermittent preventive treatment (IPT) for malaria and insecticide treated bed nets (ITN) during 
pregnancy among HIV-negative and HIV-positive pregnant women in a malaria endemic area.  
Methods: A cross sectional study of 151 women (96 HIV-negative and 55 HIV-positive) 
receiving antenatal and HIV care at an urban district hospital in Accra, Ghana from July to 
August, 2008. The women were interviewed to obtain demographic data and information on the 
use of IPT and insecticide treated bed nets (ITN) during their current pregnancy. Antenatal care 
cards were used to verify obstetric history and a record of IPT use.  
Results: HIV-positive pregnant women had significantly low uptake of all three doses of WHO 
recommended IPT compared to HIV-negative pregnant women. Dose 1: 70% and 47% p=0.019, 
Dose 2: 54.8% and 30.2%, p=0.018. Dose 3: 40% and 9.1%  p=<0.002 for HIV negative and 
HIV positive pregnant women respectively.  For ITN use, 43.8% of HIV negative and 36.4% of 
HIV positive women reported having ITNs at home, p=0.375. Of the women who had nets, 
45.2% of HIV negative and 70% HIV positive women reported having slept under a net the 
previous night, P=0.068. 
Conclusion: The low uptake of IPT among HIV-positive pregnant women is of concern in light 
of emerging evidence that malaria during pregnancy may increase the risk of MTCT of HIV. 
Comprehensive prevention of MTCT programs should include components aimed at increasing 
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Malaria is a major global public health problem that places half the world’s population at 
risk and to which approximately 1 million deaths are attributed annually.(1) 90% of these deaths 
occur in Sub-Saharan Africa and are largely caused by Plasmodium falciparum. While the 
highest burden of disease falls on children under 5 years old, pregnant women and their unborn 
babies are also very vulnerable to the disease. (2)  Approximately 30 million pregnancies occur 
in malaria endemic areas in Sub Saharan Africa, placing these women and their unborn children 
at risk. Adverse maternal outcomes include cerebral malaria, maternal anemia, placental malaria 
and maternal mortality.  These are more frequent during epidemics, and in primigravid or 
immunocompromised women. Fetal and newborn adverse outcomes include intra uterine growth 
retardation, spontaneous abortion, fetal demise, low birth weight and infant deaths. 
(3)(4)(5)(6)(7) 
 
Figure 1. Malaria risk map for P. falciparum and corresponding number of pregnancies in each 
continent in 2007.(2) 
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The extent of malaria associated adverse effects is dependent on transmission rates and 
immunity level of the population.(8) In areas of low or unstable malaria transmission, pregnant 
women do not develop significant immunity. Thus when they become parasitemic during 
pregnancy, they are at a high risk of developing severe malaria and serious adverse effects e.g. 
spontaneous abortion. In areas of high or moderate (stable) malaria transmission, pregnant 
women develop partial immunity during their subsequent pregnancies that protect them from 
developing severe malaria. These women are more likely to have asymptomatic parasitemia 
during pregnancy. However, they are still vulnerable to placental malaria which subsequently 
leads to adverse fetal outcomes.  
The pathogenesis of placental malaria is based on the sequesterization of parasitized red 
blood cells on the placenta. (1)These infected erythrocytes produce Plasmodium falciparum 
membrane protein 1( PfEMP1) which adheres to placental chondroitin sulphate A and 
hylarulonic acid. This accumulation triggers an immune response which alters the placental 
architecture and compromises maternal-fetal exchange.  (2)   PfEMP1s are highly variable in 
structure, and produce a large family of variant surface antigens (VSA) that are expressed of the 
surface of infected red blood cells. These antigens elicit antibodies which are protective against 
future infections. This protection is only partial since the VSA vary widely during the course of 
an infection or during subsequent infections.  While primigravid women are at a higher risk of 






Malaria prevention during pregnancy 
 
Early strategies to prevent the effects of malaria in pregnancy (1950s to Early 1990s) 
were based on weekly or bi-monthly chemoprophylaxis with chloroquine (CQ) in West African 
countries and dapsone-pyrimethamine or sulphadoxine-pyrimethamine (SP) in East African 
countries.(9, 10)These methods were proven to be efficacious but with time, drug resistance 
coupled with poor compliance led to low efficacy 
In 1992, Schultz and others demonstrated that two treatment doses of the anti-malarial 
drug sulfadoxine pyrimethamine ((1500/75 mg; SP) administered once in the second trimester 
and once in the third trimester, was efficacious in decreasing placental malaria in an area where 
persons receive, on average, 50 infective mosquito bites/year. (11)  SP is believed to confer a 
treatment effect by clearing or suppressing asymptomatic placental infections. It is also a slowly 
eliminated drug, thus possibly maintaining suppressive drug levels and preventing new infections 
from occurring for several weeks-a prophylactic effect. (12) 
SP has been deemed safe for administration during the second and third trimester of 
pregnancy. Pyrimethamine is in the class of anti-folate drugs that are associated with increased 
risk of birth defects when taken in the first trimester, but not during the second or third trimester. 
(13, 14) Other possible side effects associated with SP use include severe cutaneous reactions 
such as toxic epidermal necrolysis and Stevens-Johnson syndrome. (15) The risk of the 





WHO policy for malaria prevention during pregnancy in Sub Saharan Africa. 
A) Intermittent Preventive Treatment for Malaria (IPT)  
Based on this knowledge, WHO recommended Intermittent Preventive treatment (IPT) for 
malaria in pregnant women (8)This was part of a three pronged approach which included IPT, 
Insecticide Treated Nets (ITNs) and prompt case management of malaria. IPT involves the 
administration of a single curative dose of sulfadoxine pyrimethamine (1500/75 mg; SP) at pre- 
defined intervals after quickening (the mother’s recognition of fetal movement, which occurs 
early during the second trimester) and given at least 1 month apart regardless of whether the 
woman has parasitemia.  At least 2 doses are recommended during the second and third 
trimesters as part of routine scheduled antenatal clinic visits in areas of stable P. falciparum 
transmission.  
 The recommended antenatal schedule of four visits, with at least 3 occurring after 
quickening, offer an opportunity for the delivery of IPT as directly observed therapy during 
clinic visits. Recent data from Demographic and Health Surveys (DHS) show that, in the 
majority of countries in sub-Saharan Africa, more than 70% of women attend antenatal clinics at 
least once during their pregnancy and many attend repeatedly (1) 
In 2000, under the auspices of Roll Back Malaria, WHO in consultation with African 
leaders set a target to provide at least 60% of pregnant women with at least 2 doses of IPT, and 
insecticide-treated bed nets (ITN) by the year 2010. (16) By 2009, thirty-three countries in the 
African Region had adopted an IPT policy. (1) The use of IPT has led to an estimated decrease in 
incidence of: low birth weight 42%, neonatal death 38%, placental malaria 65%, ante-natal 
parasitemia 26%.  (17)   At least two doses of IPT with SP has been shown to confer benefit to 
HIV-negative semi immune pregnant women (12) 
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Despite the proven effectiveness of IPT, its use in sub-Saharan Africa remains low. (1) 
Additionally, data on IPT coverage from national surveys remain limited. Estimates of  IPT use  
in sub-Saharan Africa eight years after the Abuja  declaration show that only 5 to 44% of 
pregnant women received at least 2 doses of IPT (18) (19)   (20) (21) During 2007-2008, only 9 
high burden countries had national survey data on IPT, resulting in only 20% of pregnant women 
who received 2 or more doses of IPT (1)  
Several studies have examined factors associated with IPT coverage. Some studies have 
found associations with level of education (18) (22) However, no association has been found 
between IPT use and household wealth, knowledge of malaria, travel times to clinic and number 
of clinic visits. (18) (20) (22) (23) 
B)  Insecticide Treated Bed nets (ITN)  
As part of the three pronged approach to malaria prevention in pregnancy, WHO also 
recommends universal coverage with Insecticide treated nets (ITNs) (8)Strategies for achieving 
this goal include occasional campaigns and continuous distribution to pregnant women during 
ante-natal visits and to mothers and infants during routine immunization contacts. Coverage with 
ITNs has been rapidly increasing, with household ITN ownership reaching 31% in high burden 
countries by the end of 2008.(1) 
Studies have demonstrated the efficacy of insecticide treated nets in preventing the adverse 
effects of malaria in pregnancy.  (24)  Factors that have been associated with increased ITN use 





C) Prompt malaria case management. 
WHO also recommends prompt malaria diagnosis and case management, especially in high 
risk populations like young children or pregnant women. Malaria diagnosis is based on 
microscopy or rapid diagnostic testing (RTD), but a significant gap persists on this front. (1) In 
2008, only 22% of suspected malaria cases were tested in several high burden African countries 
that reported data to WHO. The use of RDTs was up to 13% in the reporting countries.  
The recommended treatment for uncomplicated malaria is Artemisin based Combination 
Therapy (ACT). (3) The 5 currently recommended ACTs include Artemether-lumefantrine, 
Artesunate Amodiaquine, Artesunate-mefloquine, Artesunate- Sulfadoxine pyrimethamine, and 
dihydroartemisinin piperaquine. The choice of medication is based on its efficacy in the 
particular area or country of use.  By 2009, all 42 African countries in which P. falciparum is 
endemic had adopted and implemented the use of ACTs for treatment. 
Most countries report over 50% treatment rates with 5 countries reporting 100% rates of 
treatment. However, this is in the context of properly diagnosed malaria, which only occurs in a 
minority of the total malaria cases.  For example in Ghana in 2008, approximately 22% of all 
outpatient cases were appropriately tested.  75% of those who tested positive for malaria 
reportedly had access to ACT therapy.  
Effect of HIV on Malaria during pregnancy 
There are reports that HIV infection potentiates the adverse effects of malaria during pregnancy 
(26) (27) HIV positive pregnant women have higher rates of malaria infection, and poorer 
response to anti-malarial treatment. (28) Pregnant women in malaria endemic areas develop 
immunity against placental malaria in subsequent pregnancies. However, HIV infection impairs 
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this acquired protection against placental malaria and increases prevalence of placental and 
clinical malaria in HIV-positive women of all gravidities 
Studies examining the effect of HIV on IPT efficacy showed that HIV positive women require at 
least 3 doses to achieve the same benefit observed in HIV negative women who receive 2 doses. 
(29) (28) Based on this evidence, WHO recommended 3 courses for HIV-infected pregnant 
women and for all pregnant women in areas in which the antenatal HIV prevalence exceeds 10% 
and routine HIV testing is not available World Health Organization (8) 
Approximately 1 million pregnancies each year are associated with malaria and HIV co-infection 
(30)(31).Infection with malaria is associated with higher HIV viral load, which is the single most 
important risk factor for the transmission of HIV from HIV-infected mother to the child (32) In 
addition, placental malaria in HIV positive women may alter the placental architecture, 
increasing the risk of vertical transmission of HIV. (33) There are conflicting reports on the 
effect of malaria on Mother –To-Child-Transmission (MTCT) of HIV (34) (35)(36) A recent 
study from Uganda found that placental malaria was associated with increased MTCT, even at 
low maternal viral loads (37) .  
Aims of the study 
The effects of malaria in pregnancy, the development and implementation of prevention 
strategies in Sub Saharan Africa are well known. HIV is known to confer increased vulnerability 
to malaria during pregnancy. It is crucial to target HIV-positive pregnant women for more 
effective malaria control, especially in the face of the possible contribution of malaria on MTCT 
of HIV. Current estimates of IPT coverage are on all pregnant women and to our knowledge, no 
study has attempted to evaluate IPT coverage in this particularly vulnerable group of HIV –
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positive women. We therefore designed a pilot study to evaluate the coverage of IPT in pregnant 
women in Accra Ghana, and to stratify IPT coverage on the basis of HIV serostatus. We also 
evaluated the uptake of ITN in both groups. 
Methods 
Study site 
The study was conducted at Ridge hospital, a district hospital in the capital city Accra, from July 
to August 2008. Ridge is a public hospital which is under the administration of the Ghana Health 
Service (GHS). The Ministry of Health (MOH) and the GHS oversee the public health and 
clinical care sectors in Ghana.(38) The MOH exercises oversight and overall control of the entire 
health system, and GHS is responsible for delivery of public health and clinical services. GHS 
operates at four levels: national, regional, district, and sub-district. There are over 320 hospitals, 
760 health centers, and 1120 clinics in the country. Of these facilities, 83% are in the public 
sector and 9% are faith-based institutions most of which are closely integrated with GHS. 
Malaria is hyper-endemic in all parts of the country, and transmission occurs year-round with 
seasonal variations during the rainy season. According to Ghana Health Service (GHS) health 
facility data,(39) malaria is the number one cause of morbidity, accounting for about 38% of all 
outpatient illnesses, 36% of all admissions, and 33% of all deaths in children under five years. 
Between 3.1 and 3.5 million cases of clinical malaria are reported in public health facilities each 
year, of which 900,000 cases are in children under five years. Malaria accounts for 
approximately 14% of outpatient attendance by pregnant women in Ghana, 11% of hospital 





IPT with SP was adopted as the national policy in 2004, with three doses of SP to be 
administered to HIV-negative pregnant women starting after quickening (16 weeks or thereafter). 
The doses are administered at least one month apart with the last dose administered at least one 
month before delivery. All doses of SP are to be administered under direct observation. HIV-
positive pregnant women are expected to receive monthly doses of SP after quickening (with a 
total of four doses)  
In 2006, the National Health Insurance Scheme (NHIS) was implemented. By July 2008, 50% of 
the population had been enrolled, resulting in increased attendance at health facilities.  As a 
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result, the percentage of women attending ANC clinics four or more times increased from 69% 
in 2003(40) to 78% in 2008(39)  A nationwide health facility survey in 2008 found that IPT is 
offered in 94% of facilities sampled.  Significant gains have been observed in other Malaria 
intervention indicators. Between the 2003 and 2008 ITN ownership and use, and treatment with 
ACTs increased significantly. (Table 1)   Despite strong ANC attendance and IPT coverage, 
challenges such as SP stock-outs and lack of enough trained healthcare workers continue to 
hamper IPT delivery. 
The antenatal clinic (ANC) at Ridge Hospital handles approximately 100 pregnant women each 
clinic day.  The prevalence of HIV among pregnant women attending the ANC at Ridge Hospital 
is 5%. This compares with the national average of 3.6% (41) HIV testing is carried out at the 
ANC and positive cases are referred to the HIV clinic located in the same hospital for prevention 
of Mother-To-Child Transmission of HIV (pMTCT) services. The HIV clinic also serves as a 
referral pMTCT center for pregnant women diagnosed with HIV in other clinics in the area. 
During the two months of the study, approximately sixty HIV-infected pregnant women attended 
the clinic for pMTCT care.  
INDICATOR 2003 DHS 2006 MICS 2008 DHS 
Proportion of households with one or more 
ITN 
3% 19% 33% 
Proportion of children under five years old 
who slept under an ITN the previous night 
4% 22% 28% 
Proportion of pregnant women who slept 
under an ITN the previous night 
3% NA 20% 
Proportion of women who received two or 
more doses of IPT during their last 
pregnancy in the last two years* 
0 28% 44% 
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Proportion of children under five years old 
with fever in the last two weeks who 
received treatment with ACTs* 
N/A 3% 12% 
 
Table 1: Recent Survey Estimates of Malaria Indicators (38)  
DHS: Demographic and Health Survey    MICS: Multiple Indicator Cluster Survey 
 
Enrollment and data collection 
Pregnant women attending antenatal clinic (ANC) and the HIV clinic at the hospital were invited 
to participate in the study. After explanation of the study goals and obtaining informed consent, 
an interviewer administered questionnaire was used to obtain demographic and socio-economic 
data.  Antenatal care cards that pregnant women carry with them and present to clinic throughout 
their pregnancy were used to verify the obstetric history, record of prior laboratory 
investigations, history of malaria in pregnancy and a record of IPT use.  
Data analysis 
IPT coverage 
IPT was defined as the administration of a single curative dose of sulfadoxine pyrimethamine 
((1500/75 mg; SP) Coverage was defined according to WHO recommendations as follows: 
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Dose 1: numerator= number of women who received first dose of IPT Denominator= all women 
who were 16 or over weeks in gestation. 
Dose 2:  numerator= number of women who received 2
nd
 dose of IPT, Denominator= all women 
20 weeks of gestation and over.  
Dose 3: numerator= number of women who received 3
rd
 dose of IPT. Denominator= all women 
24 weeks of gestation and over.  
Statistical analysis 
Analyses were performed using SPSS version 17. The student’s t test was used to determine the 
differences in mean age between the two study groups. Pearson chi square was used to determine 
differences between the two study groups in terms of marital status, education, occupation and 
gestation.  Logistic regressions were used to determine the effect of age, marital status, 
education, occupation and gestation on IPT uptake and ITN use. Pearson chi square                       
was used to determine the impact of IPT use on ITN use, and vice versa. 
 
Ethics statement/ Ethical considerations 
The study protocol was reviewed and approved by the Ethics Committees of the University of 
Ghana Medical School and Yale University School of Medicine. All participants provided verbal 





Baseline characteristics of the study population 
151 pregnant women (96 HIV-negative and 55 HIV-positive) participated in the study. The 
baseline demographic and obstetric characteristics of the women stratified by HIV status are 
shown in Table 1. 
 HIV-positive HIV-negative  
parameter n=96 n=55  
Age (years); mean (sd) 29.02  (5.355) 28.60 (5.384)  
≤18 years 2/100 (2.0) 1/55 (1.8)  
19-24 21/100 (21.0) 11/55 (20.0)  
25-34 60/100  (62.0) 33/55 (60.0)  
≥35 17/100 (17.0) 10/55 (18.2)  
Marital status    
Married 91 (94.8) 42 (76.4)  
Single 5 (5.2) 13 (23.6) P=0.001 
Education history    
Illiterate 13 (13.5) 9 (16.4)  
Primary education 5 (5.2) 8 (14.5)  
Junior Secondary (JSS) 47 (49) 32 (58.2)  
Senior Secondary (SSS) 16 (16.7) 5 (9.1)  
Tertiary education 10 (10.4) 0 (0)  
Other (vocational, madrasa) 5 (5.2) 1 (1.8) P=0.029 
Occupation    
unemployed 8 (8.3) 4 (7.3)  
Informal 72 (75) 47 (85.5)  
Formal  16 (16.7) 4 (7.3) P=0.239 
Gestation    
< 16 weeks 16 (16.7) 6 (10.9)  
16-19 weeks 7 (7.3) 6 (10.9)  
20-23 weeks 8 (8.3) 10 (18.2)  
≥ 24 weeks 65 (67.7) 33 (33.7) P=0.213 
    





There were no significant differences in age, occupation and gestation between the two groups. 
Most women were employed in the informal sector as market traders, hair dressers or 
seamstresses. Notably, most women visiting both the general ANC and HIV clinic were at or 
about 24 weeks gestation. There were significant differences in marital status and education level 
between the two groups: There were significantly more single women in the HIV-positive  
group, and HIV-positive women were less likely to have a senior secondary education or above.  
IPT coverage 
IPT coverage based on gestational age is shown in Figure 1. WHO recommends the first dose of 
SP after quickening (16 weeks) and subsequent doses are spaced at least 4 weeks apart. For all 
the women due for their first dose, the IPT coverage was 70% and 47% for HIV-negative and 
HIV-positive, respectively (p=0.019). For the second dose, the coverage was 54.8% and 30.2% 
for HIV-negative and HIV-positive, respectively (p=0.018). For the third dose, the coverage was 
40% and 9.1% for HIV-negative and HIV-positive women, respectively (p<0.002). HIV-positive 





FIG 1:  IPT coverage in HIV-negative and HIV-positive pregnant women.  
Patterns in IPT administration 
We investigated patterns of IPT administration following WHO recommendation of the first dose 
after quickening (16 weeks) with subsequent doses spaced 1 month apart : 20weeks  and 24 
weeks for the 2
nd
  and 3
rd
 doses respectively.  The percentage of women in the different gestation 
groups who are on dose 1, 2 and 3 are shown on table 2.  For both groups, the majority of women 






 Dose 1   Dose 2   Dose 3   
Gest. 
(wks) 
HIV - HIV + P 
value 
HIV - HIV + P 
value 
HIV - HIV + P 
value 
16-19 14.3 0 0.335       
20-23 37.5 40 0.914 0 10 0.357    
≥ 24 80 57.6 0.019 61.5 36.4 0.018 40 9.1 0.002 
 
Table 2: Percentage of women on Dose 1, 2 and 3 of IPT stratified by HIV serostatus and 
Gestational age.  
 
Predictors of IPT coverage 
The effect of individual level variables on IPT coverage was investigated for the entire study 
population. Using a logistic regression model, none of the following factors were found to be 
significant predictors of IPT use:  Age, (p=0.910) gravidity, (p=0.415) marital status, (p=0.092) 
occupation, (p=0.761) and education (0.216). In addition, using chi square analysis, ITN use was 
not found to be a significant predictor of IPT use. (p=0.074)  
ITN uptake   
We evaluated the prevalence of the use of ITNs among our study population. 43.8% of HIV-
negative and 36.4% % HIV-positive women reported having ITNs at home. P=0.375. Of the 
women who had nets, 45.2% of the HIV negative and 70% of HIV positive women reported 
having slept under a net the previous night. P=0.068.   The reasons given by participants for not 
using ITN included heat and discomfort sleeping under the net, lack of poles on their beds to 




Predictors of ITN use 
We also studied the effect of individual level variables on ITN use by the entire study population 
using logistic regressions. The following factors were not found to be significant predictors of 
ITN use: Age, (p=0.987) gravidity, (p= 0.564) marital status, (p=0.934) occupation, (p=0.927         
) and education (p=0.736). In addition, using chi square analysis, IPT use was not found to be a 
significant predictor of ITN use. (p=0.074)  
Discussion 
In this exploratory cross-sectional study, we found that pregnant women receiving antenatal care 
at an urban hospital in Ghana have IPT coverage below the WHO target to provide at minimum 
60% of pregnant women with at least 2 doses of IPT by the year 2010. In addition, HIV positive 
pregnant women had significantly lower coverage for all IPT doses.  While IPT coverage for 
HIV negative women approached the desired target with 54% of women on at least 2 doses, the 
coverage for HIV positive women fell below target with 30.2% women on at least two doses.  
Our finding of low IPT coverage is consistent with a previous study from a hospital in southern 
Ghana where 77%, 26%, and 24% of all pregnant women received one dose, at least two doses, 
and three doses of IPT respectively (42). Studies elsewhere in sub-saharan Africa show 
consistently low IPT coverage. In Malawi, a study in an urban hospital revealed that 45.1% and 
30.6% of pregnant women received one and two doses of IPT, respectively (43). A nationwide 
survey in Malawi showed that 67.5% and 29.3% of pregnant women received one, and two or 
more doses of IPT, respectively (National Statistical Office, Malawi 2001). Similar percent 
coverage was reported in a study in Kenya; 43.4% and 23.7% of pregnant women received one 
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and two doses, respectively (21).These previous studies, however, did not stratify the women 
into HIV-negative and HIV-positive categories. 
Our findings that HIV-positive women were less likely to receive IPT and to complete the 
recommended doses are of concern given the fact that HIV infection confers increased 
susceptibility to malaria in all pregnant women, regardless of their gravidity. (28) This places 
these women and their unborn children at an increased risk of malaria- associated adverse 
effects. For this reason alone, HIV-positive pregnant women need to be targeted for better 
coverage with IPT. Adding to this need are the emerging reports that malaria during pregnancy 
may increase the risk of MTCT of HIV (37) Preliminary results have not yielded uniform results 
to support this hypothesis, but the possible contribution of malaria to MTCT of HIV is of major 
public health concern, and further supports the need to target HIV-positive women for better 
malaria control.  
One of the key factors contributing to the disparity in IPT coverage between HIV-negative and 
HIV-positive pregnant women in this study was poor coordination between the different levels of 
service delivery to pregnant women in the hospital.  The general ante-natal clinic emphasized 
malaria control through IPT and ITN use. However, the focus of the HIV clinic for its pregnant 
women was the provision of antiretroviral agents to prevent MTCT of HIV. The importance of 
IPT and the possible risk association between malaria and HIV transmission was not 
emphasized. In addition, some patients attending the HIV clinic were referred from several 
satellite clinics and in most instances were not aware of the availability of free IPT services at 
the general ANC.   
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Weak links between different disease- specific programs have been identified elsewhere as a 
major cause for poor IPT delivery.  (44) Gaps in IPT delivery occur due to lack of coordination 
between Malaria and HIV control programs with reproductive services. (30) WHO recommends 
a four visit schedule for the delivery of “focused antenatal care” which would entail a “one stop 
shop” package of antenatal services that also includes malaria and HIV control. This approach 
calls for strengthened associations between the above mentioned programs.  
Our study findings also indicate late IPT uptake. While WHO recommends Dose 1 
administration after quickening (16 weeks), most of the women in our study received their first 
IPT dose at or after 24 weeks. This was the case for both the HIV-negative and HIV-positive 
groups, and contributed to low coverage especially for dose 2 and 3. In Tanzania, late ANC 
attendance, especially in rural areas was identified as a key factor hindering IPT coverage. (45) 
Most women attending late received one dose or none. Economic, psychosocial and cultural 
factors contributing to late clinic attendance that were identified in the Tanzania study include: 
Poverty and inability to pay for travel and ANC services, low decision making capacity on when 
to attend clinic, superstitions that bar women from exposing their pregnancies especially during 
the first two trimesters, and shyness/guilt associated with exposing pregnancy that is acquired 
outside a recognized marriage. For HIV-positive women, the stigma of attending a HIV clinic 
and thus being identified as suffering from the disease is a significant hindrance.  
Of the individual level variables evaluated in this study, none reached statistical significance as 
predictors of IPT coverage. These include maternal age, gravidity, marital status, occupation and 
education. It is important to note however, that some factors approached statistical significance, 
and point to possible individual level factors affecting IPT uptake. Evaluation of marital status 
showed a trend towards married women having more IPT coverage than single women. 
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(P=0.092) Additionally, a breakdown of the education levels of our study population indicated 
that illiterate women tended to have lower IPT coverage, though not statistically important. 
(p=0.068) (Appendix 1) 
Previous studies have identified education as a predictor for better IPT coverage. A study in rural 
Kenya showed that women with formal education were more likely to have received at least one 
dose of IPT. (18) Another study from Kampala, Uganda showed that the completion of 
secondary education or higher predicted the use of IPT during pregnancy. (22)   In our study 
population, HIV-positive women were more likely to be illiterate than their HIV negative 
counterparts.(p= 0.029)  Thus while analyzing for IPT coverage, education is a significant 
confounding factor. Similarly, HIV- positive women were more likely to be single. (p=0.001)  
Marital status, to our knowledge, has not been reported as a significant predictor of IPT coverage 
but is a possible confounding factor in this study.  
The use of ITN also approached statistical significance as a factor associated with higher IPT 
uptake. (P=0.074)  In a Kenyan study, Gikandi et al. reported that pregnant women who used 
ITN were more likely to have received at least one dose of IPT. (OR: 1.68, 1.20–2.36)(18)  This 
finding could reflect either that clinics that offered ITN during regular ANC visits were also 
more likely to offer IPT. It might also indicate that the women who were educated on malaria 
prevention were more likely to seek both ITN and IPT. In studies that reported low IPT 
coverage, pregnant women reported that SP was not offered to them in clinic. (46) Lack of 
awareness of the availability of IPT contributes to low coverage. (18) This highlights the need 
for more malaria specific education, both to healthcare workers and patients. Attendance to 
educational sessions that target malaria prevention and informs patients on the services available 
at their clinic has been associated with higher IPT use. (23)  
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There were no significant differences in ITN possession between HIV- negative and HIV- 
positive women.(p=0,375) However, of the women who had ITN, only 45.2% HIV- negative and 
70%  HIV- positive women reported using them. (p=0.068)  This result highlights the fact that 
having a bed net in a household does not necessarily mean that it would be used by the pregnant 
woman. Some of the women reported that they were waiting to use the net for their newborn 
baby. These women recognized the need to protect their newborns, but had limited knowledge of 
the risk of malaria during pregnancy and that the ITN would protect both the mother and the 
baby.  In addition, studies indicate that in a household that has both a pregnant woman and a 
child under 5, the latter is more likely to use the available ITN.(47)  
Other women reported lack of a proper means to hang their bed net. This finding could result 
from several factors that were outlined in the Ethiopian bed net utilization study, (48) which also 
apply to our patient population:  Firstly some household designs are not amenable to bed-net use. 
I.e., some bed nets are rectangular and require four hanging points, which might be impossible in 
a house that has a round shape, or is built from material that cannot withstand  the constant 
traction from attached bed nets e.g. mud/ dung houses. There are some nets that only require one 
attachment directly above the bed/ sleeping space, and these are more amenable to use in such a 
situation. Secondly, while it is easier to drape a net over a raised bed, some women sleep on a 
mat on the floor, or share a space that is not easily covered with a net.  Economic and 
hierarchical factors determine who sleeps on a bed, and thus who is more likely to use an ITN. In 
some families, the parents sleep on the bed, while children sleep on mats on the floor. In others, 
it might be the women or girls who sleep on the floor. These findings are important, especially to 
organizations and companies that design insecticide treated bed-nets for use in a population of 
low social economic means such as ours.   
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Some women cited the difficulty of using bed-nets during times of high ambient temperatures. 
This problem is exacerbated for women who live in close quarters. 
We evaluated the effect of individual factors such as age, gravidity, marital status, occupation 
and education on ITN use. None of these factors were significant predictors of ITN use in our 
population. However, IPT use showed a close to significant association with ITN use as 
mentioned above. Other studies have identified education (18) and high knowledge of malaria 
(23) as predictors of ITN use. Our logistic regression analysis was hampered by low sample size, 
since only 62/151 (41%) women in our total sample reported using ITNs.  
Our study indicates that HIV-positive women who had bed nets were more likely to use them, 
although the result did not achieve statistical significance. (p=0.068) To our knowledge, studies 
that evaluate ITN uptake in pregnant women do not stratify based on HIV serostatus. This is an 
interesting finding that requires further evaluation and corroboration. It is a positive indication 
that HIV- positive women in our study population, who are known to be at risk for more severe 
malaria, were more likely to adhere to malaria prevention strategies that were presented to them. 
Conclusion 
Our findings suggest the need to intensify the strategies to increase IPT coverage for HIV- 
positive pregnant women in sub-Saharan Africa. Increasing IPT coverage will not only avert the 
known malaria-related adverse effects on the mother and the child, but possibly lead to a further 
reduction in the incidence of MTCT of HIV in the sub-region. There should be a concerted effort 
to integrate malaria prevention during pregnancy into comprehensive PMTCT programs for 
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Results of Logistic regressions, evaluating which individual level factors predict IPT use. 
 95% C.I.for EXP(B) 
 B S.E. Wald df Sig. Exp(B) Lower Upper 
Age .005 .044 .013 1 .910 1.005 .922 1.096 
Mar 1.877 1.116 2.830 1 .092 6.533 .734 58.171 
Occup   .547 2 .761    
Occup(1) .392 1.111 .125 1 .724 1.481 .168 13.066 
Occup(2) .591 .805 .540 1 .462 1.806 .373 8.746 
educ   7.057 5 .216    
educ(1) -2.350 1.286 3.341 1 .068 .095 .008 1.185 
educ(2) -2.428 1.477 2.702 1 .100 .088 .005 1.595 
educ(3) -1.193 1.068 1.248 1 .264 .303 .037 2.460 
educ(4) -.771 1.195 .416 1 .519 .463 .044 4.815 
educ(5) -.004 1.388 .000 1 .998 .996 .066 15.132 
Constant -2.378 1.922 1.530 1 .216 .093   
 
Key: Mar= marital status, single or married 
Occup=occupation. 1= informal sector, 2= formal sector 
Educ= education. 1=illiterate, 2= primary, 3= Junior secondary, 4= senior secondary, 5= Tertiary 
